Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation

Overview

Información sobre este estudio

The purpose of this study is to evaluate the safety and effectiveness of the VitaSmart Liver Machine Perfusion System by comparing clinical outcomes in patients undergoing liver transplantation with ex-vivo liver preservation using static cold storage (SCS) followed by hypothermic oxygenated machine perfusion (HOPE) versus SCS only.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Donation after Brain Death (DBD) Liver Inclusion Criteria (one or more):

- Donor age 50-85 years

- Anticipated cold ischemia time 10-15 hours (excluding HOPE duration)

- Macrosteatosis 10-40%

- Terminal ALT 250-1500 IU/ml

- Peak ALT within 3 days 1000-3000 IU/ml

- Terminal total bilirubin 2-4 mg/dl

Donation after Brain Death (DBD) Liver Exclusion Criteria (one or more):

- Donor age <18 or >85 years

- Anticipated cold ischemia >15 hours

- Macrosteatosis >40%

- Terminal ALT >1500 IU/ml

- Peak ALT within 3 days >3000 IU/ml

- Terminal total bilirubin >4 mg/dl

- Presence of hemodynamic and/or anatomical donor abnormalities that, in the opinion of
the Investigator, make the liver allograft unsuitable for transplant into the
recipient subject

- Liver intended for split transplant

- Liver from living donor

- Donor terminal serum Na >160 mmol/L

Donation after Cardio-circulatory Death (DCD) Liver Inclusion Criteria (all):

- Donor age 18-60 years

- Anticipated cold ischemia time <12 hours (excluding HOPE duration)

- Functional warm ischemia time ≤35 minutes, defined as interval from the time of onset
of donor hypotension (MAP <50mmHg) until the time of donor cross clamp

- Macrosteatosis ≤20%

- Terminal ALT ≤500 IU/ml

- Peak ALT within 3 days ≤2000 IU/ml

- Terminal total bilirubin ≤3 mg/dl

Donation after Cardio-circulatory Death (DCD) Liver Exclusion Criteria (one or more):

- Presence of hemodynamic and/or anatomical donor abnormalities that, in the opinion of
the Investigator, make the liver allograft unsuitable for transplant into the
recipient subject

- Liver intended for split transplant

- Liver from living donor

- Donor terminal serum Na >160 mmol/L

Recipient Inclusion Criteria (one or more):

- Subject (or legally authorized representative) is able to provide informed consent and
HIPAA authorization

- Subject is male or female and at least 18 years of age

- Subject is registered as an active liver recipient on the UNOS waiting list for liver
transplantation

- Subject will undergo primary liver transplantation

- Subject is willing to comply with the study requirements and procedures

- Subject with hepatocellular carcinoma as indication for Orthotopic Liver
Transplantation; the tumor must be within Milan Criteria or down-staged to Milan
Criteria

Recipient Exclusion Criteria (one or more):

- Subject will undergo multiple organ transplantations (liver-kidney, liver-lung, etc.)

- Subject is listed for liver transplantation due to fulminant liver failure (UNOS
status 1A)

- Subject is pregnant

- Subject is on respiratory (ventilator dependent) and/or cardiocirculatory support
(requires at least one intravenous inotrope to maintain hemodynamics)

- Subject is enrolled in an interventional clinical trial with an investigational drug
or device

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/20/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Shennen Mao, M.D.

Cerrado para la inscripción

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publicaciones

Publications are currently not available
.
CLS-20528849

Mayo Clinic Footer